Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

01/18/01	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
23/18/23	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
09/18/09	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
21/18/21	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
28/18/28	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

03/18/03	TxCell : acquisition par Sangamo finalisée
27/18/27	TxCell : retrait obligatoire ce jeudi
26/18/26	TxCell : près de sept millions d'actions apportées à l'OPAS
23/18/23	TXCell : Sangamo Therapeutics dépasse les 90%
15/18/15	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
ARGENX SE	+1.44%	-1.25%	+64.25%	+114.23%	5.52TCr
WUXI APPTEC CO., LTD.	+4.60%	+3.02%	+57.38%	+48.98%	4.58TCr
BIONTECH SE	-1.44%	+0.39%	-14.68%	-17.33%	2.3TCr
INSMED INCORPORATED	-2.69%	-2.10%	-6.70%	+374.02%	2.08TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	-0.84%	+27.88%	-20.46%	1.63TCr
GENMAB A/S	+0.58%	+1.08%	+18.85%	-37.32%	1.54TCr
EXELIXIS, INC.	-1.01%	-2.30%	+28.59%	+174.08%	1.3TCr
PHARMAESSENTIA CORPORATION	+4.95%	+11.70%	+125.78%	+252.19%	1.24TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+0.14%	+29.05%	-	1.24TCr
Average	+1.27%	+2.23%	+36.71%	+111.05%	2.38TCr
Weighted average by Cap.	+1.63%	+1.48%	+40.78%	+101.14%

TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile